Learn more about each of our Seminars for the 2024 Masterclass Series

SCDAA’s Masterclass speaker series brings top SCD leaders and community experts together to share their expertise on cutting edge SCD topics.

In December of 2023, groundbreaking gene therapy treatments were approved. SCDAA’s 2024 Masterclass will explore the national and global impacts of these treatments. We will also shine a spotlight on diversity in our community and look at our experiences from new perspectives.

Seminar Three

What Does the Future Hold for Sickle Cell Disease?

Saturday, October 26, 2024

The third and final 2024 seminar features a panel discussion recorded live at SCDAA Convention 2024 in Atlanta, GA.

Seminar Two

Anemia Falciforme: La Experiencia Latina [Sickle Cell Disease: The Latino Experience]

Saturday, July 13, 2024 | 12 p.m. EST

Enroll today for our next Masterclass en Espanol with English translation on July 13, 2024 at 12:00 - 1:30 p.m. EST.

Anemia Falciforme: La Experiencia Latina [Sickle Cell Disease: The Latino Experience] will feature panelists Ofelia Alvarez, M.D., Laura De Castro, M.D., Sra. Ivett Martinez, and Srta. Sarai Santiago to discuss the treatment of Sickle Cell Disease, available resources and marrow and blood donations, the experience and advice coming from a mom caretaker, and a patient’s experience with sickle cell anemia.

Seminar One

Global Implications of Gene Therapy: How You Can Prepare

Saturday, April 27, 2024 | 10 a.m. EST

Our Masterclass series is back! Join us for our first seminar on Saturday, April 27 at 10 a.m. ET. The session, hosted in collaboration with the Global Alliance of Sickle Cell Disease Organizations (GASCDO), will discuss the global implications of gene therapy and how you can prepare. Experts from the clinical, warrior and caregiver communities will provide up-to-date, relevant information to the global sickle cell community. Learn what you need to know to make an informed decision about this potentially curative and life-changing therapy and have your questions answered.